Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	1	25,449	N/A	N/A	64.00% (48.80% to 74.70%)
Confirmed symptomatic COVID‐19 after complete vaccination	1	25,480	N/A	N/A	72.80% (58.10% to 82.40%)
Severe or critical COVID‐19 after complete vaccination	N/A	N/A	N/A	N/A	N/A
All‐cause mortality	N/A	N/A	N/A	N/A	N/A
Serious adverse events	2	27,029	Risk Ratio (M‐H, Random, 95% CI)	0.83 (0.60 to 1.15)	N/A
Systemic reactogenicity events	2	27,029	Risk Ratio (M‐H, Random, 95% CI)	0.99 (0.95 to 1.03)	N/A
Any adverse event	2	27,029	Risk Ratio (M‐H, Random, 95% CI)	0.96 (0.93 to 0.98)	N/A
Local reactogenicity events	2	27,029	Risk Ratio (M‐H, Random, 95% CI)	0.88 (0.85 to 0.92)	N/A